18Apr 2022
Targeting oncometabolism to maximize immunotherapy in malignant brain tumors

Targeting oncometabolism to maximize immunotherapy in malignant brain tumors

Brain tumours result in significant morbidity and mortality in both children and adults. However, recent data indicate that immunotherapies may offer a survival benefit after the standard of care has failed for malignant brain tumours. Recently, oncometabolism has emerged as an adjunct modality for combinatorial treatment approaches necessitated by the aggressive, refractory nature of high-grade glioma and other progressive malignant brain tumours. Herein, the study summarizes preclinical and early phase clinical trial research of oncometabolism-based therapeutics that may augment immunotherapy by exploiting brain tumours' biochemical and genetic underpinnings. The study also examines metabolic pathways related to immune cells that target tumour cells, termed "tumour immunometabolism". Lastly, the study summarize future directions targeting metabolism combined with emerging therapies such as oncolytic virotherapy, vaccines, and chimeric antigen receptor T cells.

  • #oncology

Like

Save

Share